Familial Chylomicronemia Syndrome Market to Observe Stupendous Growth During the Forecast Period | Key Companies – Novelion, Arrowhead, Akcea, Ionis Pharma, Amryt Pharma, and Others

Delveinsight Business Research LLP
DelveInsight’s “Familial Chylomicronemia Syndrome Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Familial Chylomicronemia Syndrome Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Familial Chylomicronemia Syndrome market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Familial Chylomicronemia Syndrome: An Overview

Familial Chylomicronemia Syndrome (FCS) is a rare genetic lipid disorder, which is characterized by the increase in the triglycerides (TGs) level due to reduction in the LPL, which is an enzyme that helps to break down chylomicrons (CMs) in the body. The reduction in the LPL leads to the buildup of CMs which are rich in triglycerides.

The current treatment of Familial Chylomicronemia Syndrome (FCS) involves the restriction in the dietary fat intake allied with traditional TG-lowering agents like fibrates, statins, and niacin’s. However, there is no US Food and Drug Administration (FDA) approved drug for the treatment of FCS, but in May 2019, Waylivra (volanesorsen) was conditionally approved by European Commission (EC) for the treatment of FCS.

Nearly 70% of patients reported that FCS interfered significantly with their self-worth, emotional well-being, sleep, and mental functioning. The dietary restriction of fat intake and traditional TG-lowering agents is not so efficacious in these patients.

Familial Chylomicronemia Syndrome Market Key Facts

The total prevalent population of Familial Chylomicronemia Syndrome in the 7MM was assessed to be 5,801 in 2017 and is expected to increase during the study period.

Among the European 5 countries, Germany had the highest prevalent population of Familial Chylomicronemia Syndrome (FCS), followed by France and the United Kingdom. On the other hand, Spain had the lowest prevalent population of FCS, in 2017.

Japan accounts for about 22% of the total 7MM prevalent population of Familial Chylomicronemia Syndrome (FCS) (in 2017).

Among the 7MM, the highest number of prevalent cases of Familial Chylomicronemia Syndrome (FCS) were estimated in the United States.

Familial Chylomicronemia Syndrome Market

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Familial Chylomicronemia Syndrome market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives a thorough detail of the Familial Chylomicronemia Syndrome market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Familial Chylomicronemia Syndrome Epidemiology

The epidemiology section covers insights about the historical and current Familial Chylomicronemia Syndrome patient pool and forecasted trends for every seven major countries (7MM)  from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Familial Chylomicronemia Syndrome (FCS) Epidemiology Segmentation – 

Total Prevalence of Familial Chylomicronemia Syndrome 

Total Diagnosed Prevalence of Familial Chylomicronemia Syndrome

Age-specific Diagnosed Prevalence of Familial Chylomicronemia Syndrome

Treated Patient Pool of Familial Chylomicronemia Syndrome

Severity- Specific Diagnosed Prevalence of Familial Chylomicronemia Syndrome

Familial Chylomicronemia Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Familial Chylomicronemia Syndrome market or expected to get launched in the market during the study period. The analysis covers Familial Chylomicronemia Syndrome market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Familial Chylomicronemia Syndrome Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/familial-chylomicronemia-syndrome-market

Familial Chylomicronemia Syndrome Therapeutics Analysis

The dynamics of the Familial Chylomicronemia Syndrome (FCS) market is anticipated to transform in the coming years owing to the rise in numbers of companies taking interest in the development of drugs for FCS.

Some of the key companies in the Familial Chylomicronemia Syndrome (FCS) Market include – 

Arrowhead

Akcea Therapeutics

Ionis Pharmaceuticals

Amryt Pharma

Novelion Therapeutics

And many others

Familial Chylomicronemia Syndrome (FCS) Therapies Covered in the report include:

AKCEA-ANGPTL3-LRX

ARO-APOC3

Lomitapide

AKCEA -APOCIII – LRx

And many others.

Get More Detailed Insights into the Emerging Therapies & Key Companies:-  https://www.delveinsight.com/sample-request/familial-chylomicronemia-syndrome-market

Table of Content

1. Key Insights

2. Executive Summary 

3. Familial Chylomicronemia Syndrome Competitive Intelligence Analysis

4. Familial Chylomicronemia Syndrome Market Overview at a Glance

5. Familial Chylomicronemia Syndrome Disease Background and Overview

6. Familial Chylomicronemia Syndrome Patient Journey

7. Familial Chylomicronemia Syndrome Epidemiology and Patient Population

8. Familial Chylomicronemia Syndrome Treatment Algorithm, Current Treatment, and Medical Practices

9. Familial Chylomicronemia Syndrome Unmet Needs

10. Key Endpoints of Familial Chylomicronemia Syndrome Treatment

11. Familial Chylomicronemia Syndrome Marketed Products

12. Familial Chylomicronemia Syndrome Emerging Therapies

13. Familial Chylomicronemia Syndrome Seven Major Market Analysis

14. Attribute Analysis

15. Familial Chylomicronemia Syndrome Market Outlook (7 major markets)

16. Familial Chylomicronemia Syndrome Access and Reimbursement Overview

17. KOL Views on the Familial Chylomicronemia Syndrome Market.

18. Familial Chylomicronemia Syndrome Market Drivers

19. Familial Chylomicronemia Syndrome Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Request Sample Report here:- https://www.delveinsight.com/sample-request/familial-chylomicronemia-syndrome-market

Other Trending Healthcare Reports By DelveInsight

Malignant Pleural Mesothelioma (MPM) Market

Malignant Pleural Mesothelioma (MPM) Market is anticipated to grow in the coming years owing to the improvement in healthcare spending across the world, rising prevalence, and the active participation of the key companies in the therapeutics domain such as Sellas, Polaris Pharma, Targovax, among others.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/